Moderna MRNA is expected to report first-quarter 2025 earnings on May 1, before the opening bell. The company’s earnings beat ...

The latest trading day saw Moderna (MRNA) settling at $27.19, representing a -0.75% change from its previous close.

Moderna faces challenges with respiratory vaccine sales and strong competition. Click here to read an analysis of MRNA stock ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

FRIDAY, April 25, 2025 (HealthDay News) -- On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in Moderna to expedite the creation of a ...

Bernstein lowered the firm’s price target on Moderna (MRNA) to $28 from $39 given recent political headwinds for the stock, while keeping a ...

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

BofA lowered the firm’s price target on Moderna (MRNA) to $26 from $32 and keeps an Underperform rating on the shares. For 2025, the firm’s ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

SK bioscience, the biopharmaceutical arm of South Korea's SK Group, said on Wednesday it has achieved a "final victory" in a ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...